In April 2025, the FDA granted accelerated approval to Vanrafia (atrasentan), a blood pressure drug now cleared to treat IgA nephropathy, a rare kidney disease that disproportionately strikes young adults and can quietly progress to kidney failure. Manufactured by Novartis, Vanrafia is the first and only selective endothelin A receptor antagonist approved specifically to reduce proteinuria — the dangerous spillage of protein into urine — in adults with primary IgA nephropathy at risk of rapid disease progression. For the estimated 150,000 Americans living with this condition, many of whom have watched their kidney function deteriorate with limited pharmaceutical options, this approval represents a genuine shift in the treatment landscape.
Vanrafia is not the only blood pressure drug class making waves in kidney care. Filspari (sparsentan), made by Travere Therapeutics, received full FDA approval in September 2024 to slow kidney function decline in adults with the same condition, and it may soon expand into focal segmental glomerulosclerosis (FSGS), another rare and historically undertreated kidney disease. Together, these approvals are part of an unprecedented surge: the FDA approved six kidney disease medications across four indications in 2025 alone. This article breaks down what these drugs actually do, how they differ, what the clinical evidence shows, and what patients and caregivers — particularly those already navigating cognitive health challenges — should understand about the connection between kidney disease and brain health.
Table of Contents
- What Blood Pressure Drug Was Approved for a Rare Kidney Condition, and How Does It Work?
- Understanding IgA Nephropathy and Why It Has Been So Difficult to Treat
- How Filspari Differs From Vanrafia and What Its Full Approval Means
- What Patients and Caregivers Should Discuss With Their Doctors
- The Kidney-Brain Connection and Why Dementia Caregivers Should Pay Attention
- Other Kidney Drug Approvals Worth Knowing About
- What Comes Next for Kidney Disease Treatment
- Conclusion
- Frequently Asked Questions
What Blood Pressure Drug Was Approved for a Rare Kidney Condition, and How Does It Work?
Vanrafia (atrasentan) works by blocking endothelin-1, a hormone that tightens blood vessels and ratchets up pressure inside the kidneys. When endothelin-1 goes unchecked in a person with IgA nephropathy, it drives kidney stress, swelling, and scarring — the kind of slow-motion damage that eventually leads to dialysis or transplant. By selectively targeting the endothelin A receptor, atrasentan reduces that internal pressure without broadly suppressing the immune system, which is what older treatments for IgA nephropathy typically required. The drug is taken as a once-daily oral pill, added on top of standard supportive care such as a RAS inhibitor, with or without an SGLT2 inhibitor. The clinical evidence backing this approval comes from the ALIGN study, where patients taking atrasentan alongside a RAS inhibitor achieved a 36.1 percent reduction in proteinuria compared to placebo. Results appeared as early as week six and held steady through week 36.
That speed matters because proteinuria is not just a lab number — it is a direct marker of ongoing kidney damage. The faster you bring it down, the more kidney function you potentially preserve. However, this is still an accelerated approval, meaning the FDA considered the proteinuria reduction a reasonably likely predictor of clinical benefit. Novartis must provide confirmatory data on eGFR decline — a more definitive measure of kidney function — by week 136, with results expected in 2026. It is worth noting that accelerated approval is not the same as provisional or experimental status. Patients can access the drug now through prescription. But the conditional nature of the approval means there is still an open question about whether the proteinuria reduction translates into the outcome that ultimately matters most: keeping patients off dialysis and preserving long-term kidney function.
Understanding IgA Nephropathy and Why It Has Been So Difficult to Treat
IgA nephropathy, also called Berger’s disease, occurs when immunoglobulin A antibodies — part of the body’s normal immune defense — deposit in the kidneys and trigger chronic inflammation. Over months and years, that inflammation causes scarring that progressively destroys the kidney’s filtering ability. It is a leading cause of kidney failure in young adults, which makes it particularly cruel in its timing, often hitting people in their twenties and thirties who may not realize anything is wrong until significant damage has already occurred. Historically, treatment options have been limited and blunt. Doctors relied primarily on blood pressure medications like ACE inhibitors or angiotensin receptor blockers to reduce proteinuria, along with immunosuppressive drugs like corticosteroids that carried substantial side effects including weight gain, bone loss, and increased infection risk.
For many patients, these interventions slowed progression but did not stop it. A person diagnosed at 30 might spend the next two decades watching their kidney function numbers inch downward, knowing that dialysis or transplant was the likely endpoint. The arrival of targeted therapies like Vanrafia and Filspari does not erase that reality, but it does give nephrologists more precise tools to intervene earlier and more effectively. However, not every patient with IgA nephropathy will be a candidate for these new drugs. Vanrafia’s approval specifically targets adults at risk of rapid disease progression, which means patients with stable, slowly progressing disease may not qualify or may not benefit enough to justify the side effects. Those side effects — peripheral edema, anemia, and liver transaminase elevation were each reported at rates at least two percent higher than placebo — are manageable but real, and they require monitoring.
How Filspari Differs From Vanrafia and What Its Full Approval Means
Filspari (sparsentan) takes a different pharmacological approach. Rather than selectively blocking just the endothelin A receptor, it is the only dual endothelin angiotensin receptor antagonist, or DEARA, on the market — meaning it simultaneously blocks both endothelin receptors and angiotensin II receptors. Think of it as combining the mechanism of a traditional blood pressure drug with the newer endothelin-blocking approach in a single molecule. Travere Therapeutics earned full FDA approval for Filspari in September 2024, a meaningful distinction from Vanrafia’s accelerated approval because it means the confirmatory clinical benefit data has already been reviewed and accepted. This full approval status carries practical weight.
Insurers are generally more willing to cover fully approved drugs without extensive prior authorization hurdles, and prescribers may feel more confident reaching for Filspari when they have a patient whose kidney function is actively declining. Travere has also filed a supplemental new drug application seeking approval for Filspari in focal segmental glomerulosclerosis, another rare kidney disease that currently has no FDA-approved treatment at all. If the FDA approves that expanded indication — with a target decision date of April 13, 2026, extended from January 2026 after the agency requested additional data — Filspari would become the first and only approved therapy for FSGS. One practical update worth noting: the FDA approved changes to Filspari’s risk evaluation and mitigation strategy in 2025, reducing the required liver function monitoring from monthly to every three months and removing the embryo-fetal toxicity monitoring requirement. For patients already on the drug, that means fewer blood draws and fewer clinic visits, which is a meaningful quality-of-life improvement for people managing a chronic disease.
What Patients and Caregivers Should Discuss With Their Doctors
Choosing between Vanrafia and Filspari — or deciding whether either drug is appropriate — requires a conversation that goes beyond reading an approval headline. The two drugs are not interchangeable. Vanrafia’s selective endothelin A blockade may produce fewer off-target effects, but its accelerated approval status means the long-term kidney function data is still being collected. Filspari’s dual mechanism offers broader receptor coverage and carries full approval, but its side effect profile and drug interaction considerations are different. A nephrologist will weigh factors like the patient’s current proteinuria level, rate of eGFR decline, existing medications, liver function, and fluid retention risk.
For caregivers who are already managing a loved one’s cognitive health — perhaps alongside an early dementia diagnosis — adding a kidney disease treatment introduces another layer of medication management. Both drugs require liver function monitoring, and both can cause fluid retention that may complicate heart failure or other cardiovascular conditions common in older adults. It is not enough to know that a drug is approved; the question is whether it fits into the specific medical picture of the person sitting in the exam room. Patients already taking an angiotensin receptor blocker, for example, would not add Filspari’s built-in angiotensin blockade without their doctor adjusting the existing regimen. These are conversations that require a nephrologist, not a headline.
The Kidney-Brain Connection and Why Dementia Caregivers Should Pay Attention
Kidney disease and cognitive decline are more closely linked than most people realize. The kidneys and the brain share similar small-vessel architecture, and conditions that damage one often damage the other. Chronic kidney disease is an independent risk factor for cognitive impairment and dementia, with research showing that declining kidney function correlates with accelerated brain aging, white matter lesions, and increased risk of both vascular dementia and Alzheimer’s disease. Proteinuria itself — the very thing Vanrafia and Filspari are designed to reduce — has been associated with worse cognitive outcomes in longitudinal studies. This connection matters because kidney disease is frequently underdiagnosed or undertreated in older adults who are already being monitored for cognitive decline.
A person seeing a neurologist for memory concerns may not be getting regular kidney function tests, and their nephrologist may not be screening for early cognitive changes. The approval of more effective kidney-protective drugs creates an opportunity to have a broader conversation about preserving both kidney and brain health, particularly since the vascular damage that drives both conditions shares common risk factors like hypertension, diabetes, and inflammation. However, a critical limitation applies: neither Vanrafia nor Filspari has been studied for cognitive outcomes. No one should take these drugs expecting them to prevent or slow dementia. The relevance for brain health is indirect — by better preserving kidney function, you may reduce one of the vascular risk factors that contributes to cognitive decline. That is a reasonable hypothesis, not a proven benefit.
Other Kidney Drug Approvals Worth Knowing About
The FDA’s 2025 kidney drug approvals extend well beyond IgA nephropathy. Fabhalta (iptacopan) became the first treatment approved for C3 glomerulopathy, or C3G, a rare kidney disease driven by overactivation of the complement immune system.
Empaveli (pegcetacoplan) was also approved for C3G, giving patients and doctors a second option in a disease that previously had none. Meanwhile, Voyxact (sibeprenlimab), a monoclonal antibody self-injected every four weeks, offers yet another mechanism of action for IgA nephropathy — working through the immune system rather than the vascular system. For a patient who cannot tolerate endothelin receptor antagonists due to fluid retention or liver concerns, sibeprenlimab represents a meaningfully different treatment path.
What Comes Next for Kidney Disease Treatment
The next twelve months will bring pivotal data points. Novartis must deliver confirmatory eGFR results for Vanrafia by 2026 to maintain its approval, and the FDA’s decision on Filspari for FSGS — expected by April 13, 2026 — could open the first approved treatment pathway for a disease that has forced patients to rely on off-label immunosuppressants for decades. More broadly, the fact that six kidney disease medications were approved across four indications in a single year suggests that the field has reached a tipping point, driven by better understanding of disease mechanisms and regulatory willingness to use accelerated pathways for conditions with high unmet need.
For patients, caregivers, and clinicians navigating the intersection of kidney health and cognitive aging, these developments deserve close attention. Kidney disease rarely makes headlines the way Alzheimer’s drugs do, but the organ damage it causes ripples outward through every system in the body — including the brain. The expanding treatment toolkit means more opportunities to intervene, more reasons to screen, and more conversations worth having at the next doctor’s visit.
Conclusion
The approval of Vanrafia and the expanded availability of Filspari mark a turning point for people living with IgA nephropathy and potentially for those with FSGS. After years of managing a progressive disease with limited and often blunt tools, patients now have access to targeted therapies that address the specific vascular mechanisms driving kidney damage. Combined with other 2025 approvals like Fabhalta, Empaveli, and Voyxact, the treatment landscape for rare kidney diseases has shifted from scarcity to genuine choice — each drug with distinct mechanisms, trade-offs, and monitoring requirements. For anyone involved in dementia care or brain health advocacy, these kidney disease approvals are a reminder that organ systems do not decline in isolation.
Protecting the kidneys may be one piece of a broader strategy for preserving cognitive function, even if the direct evidence linking these specific drugs to brain outcomes does not yet exist. The practical next step is straightforward: if you or someone you care for has kidney disease alongside cognitive concerns, bring both conditions into the same conversation with their medical team. The drugs are better now. The monitoring is evolving. The window for meaningful intervention is wider than it has ever been.
Frequently Asked Questions
What is IgA nephropathy?
IgA nephropathy, also known as Berger’s disease, is a rare kidney disease in which IgA antibody deposits accumulate in the kidneys, causing chronic inflammation and progressive scarring. It is a leading cause of kidney failure in young adults, and it often progresses silently for years before diagnosis.
What is the difference between Vanrafia and Filspari?
Vanrafia (atrasentan) selectively blocks the endothelin A receptor to reduce proteinuria and received accelerated FDA approval in April 2025. Filspari (sparsentan) is a dual-action drug that blocks both endothelin receptors and angiotensin II receptors, and it received full FDA approval in September 2024. Both treat IgA nephropathy but through somewhat different mechanisms, and Filspari is also being reviewed for FSGS.
Does Vanrafia have full FDA approval?
Not yet. Vanrafia received accelerated approval, which is based on proteinuria reduction as a surrogate endpoint. Continued approval depends on Novartis providing confirmatory data showing that the drug actually slows the decline in kidney function (eGFR), with results expected in 2026.
Can these kidney drugs help prevent dementia?
Neither Vanrafia nor Filspari has been studied for cognitive outcomes. However, chronic kidney disease is an established risk factor for cognitive decline and dementia due to shared vascular damage. Better kidney disease management may indirectly support brain health, but this remains a hypothesis rather than a proven benefit.
What are the main side effects of Vanrafia?
In clinical trials, the most common side effects occurring at rates at least two percent higher than placebo were peripheral edema (fluid retention and swelling), anemia, and elevated liver enzymes. Liver function monitoring is required during treatment.
Are there other new treatments for rare kidney diseases besides these two drugs?
Yes. In 2025, the FDA also approved Fabhalta (iptacopan) and Empaveli (pegcetacoplan) for C3 glomerulopathy, and Voyxact (sibeprenlimab) for IgA nephropathy. In total, six kidney disease medications were approved across four indications in 2025.
